Minocycline + Placebo

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Multiple Sclerosis, Relapsing-Remitting

Conditions

Multiple Sclerosis, Relapsing-Remitting

Trial Timeline

Feb 1, 2006 → Apr 1, 2011

NCT ID

NCT01134627

About Minocycline + Placebo

Minocycline + Placebo is a phase 2 stage product being developed by Merck for Multiple Sclerosis, Relapsing-Remitting. The current trial status is terminated. This product is registered under clinical trial identifier NCT01134627. Target conditions include Multiple Sclerosis, Relapsing-Remitting.

What happened to similar drugs?

20 of 20 similar drugs in Multiple Sclerosis, Relapsing-Remitting were approved

Approved (20) Terminated (0) Active (0)

✅Mirabegron + PlaceboAstellas PharmaApproved

✅Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved

✅TeclistamabJohnson & JohnsonApproved

✅BortezomibJohnson & JohnsonApproved

✅DaratumumabJohnson & JohnsonApproved

✅Mavenclad®MerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01134627	Phase 2	Terminated	Feb 1, 2006	Apr 1, 2011	Multiple Sclerosis, Relapsing-Remitting

Competing Products

20 competing products in Multiple Sclerosis, Relapsing-Remitting

See all competitors

Product	Company	Stage	Hype Score
mRNA-1195	Moderna	Phase 2	0
NEX-20A	Nanexa AB	Phase 1	23
mRNA-2736	Moderna	Phase 1	0
mRNA-2808	Moderna	Phase 2	0
Placebo + Pirtobrutinib	Eli Lilly	Phase 2	27
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide	Eli Lilly	Phase 1/2	32
agenT-797	MiNK Therapeutics	Phase 1	19
Duloxetine Hydrochloride (HCI) + Placebo	Eli Lilly	Phase 3	40
Temferon	Genenta Science	Phase 1/2	14
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)	Celltrion	Phase 3	47
CT-P53 + US-Ocrevus + EU-Ocrevus	Celltrion	Phase 3	47
CS-0777 tablets + CS-0777 tablets + CS-0777 tablets	Daiichi Sankyo	Phase 1	29
ASP7487, Velcade, Dexamethasone	Astellas Pharma	Phase 1/2	24
PHE885	Novartis	Phase 2	27
Mirabegron + Placebo	Astellas Pharma	Approved	43
Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo	Astellas Pharma	Approved	43
Denileukin Diftitox (Ontak)	Eisai	Phase 1	21
Palonosetron	Eisai	Phase 2	35
BIW-8962	Kyowa Kirin	Phase 1	21
KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)	Kyowa Kirin	Phase 2	35